Contrastive Analysis Of Between TEC And TE Neoadjuvant Chemotherapy For Breast Cancer

Objective: To compare the efficacy and adverse reaction of the two neoadjuvant chemotherapy regimens on the basis of docetaxel and epirubisin with or without cyclophosphamide(TEC/TE) for breast cancer patients.Methods: The clinicopathological data of totally of 139 patients with stage â…¡-â…¢ breast invasive ductal cancer in our hospital from January 2012 to April 2014 were restropectively analyzed. All patients received four cycles of neoadjuvant chemotherapy, including 68 with TEC regimen(docetaxel 75mg/m2+ epirubicin 60 mg / m2 + cyclophosphamide 500 mg / m2) and 71 with TE regimen(docetaxel 75mg/m2+ epirubicin 60 mg / m2). RECIST criteria was used to evaluate the clinical efficacy,and the patients with complete response(CR) and partial response(PR) were considered as clinically effective cases. MILLER criteria was used to evaluated the pathological efficacy, and the patients in stag â…¤+â…£+â…¢ were considered as pathological effective cases. Moreover, the adverse reactions including nausea, vomiting, granulocytopenia and cardiac toxicity were also compared between two groups. Rank data were compared using non-parametric test, count data using chi-square test.Results: The pathological complete response(PCR) rate and CR rate in TEC group are 13.85% and 10.29% respectively, higher than 11.27% and 5.63% in TE group, but the difference was not statistically significant(Z=-1.804,-1.336; P=0.071, 0.181). The pathologically effective rate was 76.47% in TEC group, significantly higher than 61.97% in TE group(?2= 4.201; P= 0.040), but there was no significant difference with clinically effective rate between both groups(72.06% vs 61.97, ?2=1.594,P = 0.206).The breast-conserving rate were 5.88% in TEC group and 8.45% in TE group, and the difference was not significant(?2=0.066, P=0.797).The common side effects including nausea/vomiting, granulocytopenia and cardiac toxicity showed no significant difference between two groups(Z=-1.670,-0.667,-1.326; P=0.095, 0.505, 0.185).Conclusions: Compared with TE regimen, the patients who receive TEC regimen for neoadjuvant chemotherapy are more prone to pathological response without increasing adverse reactions. TEC regimen has a good prospect in neoadjuvant chemotherapy for breast cancer patients.